Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1 Trial of Pedmark in Men Receiving Cisplatin for Metastatic Germ Cell Tumor

NCT07218913 is registered in ClinicalTrials.gov with City of Hope Medical Center as lead sponsor.

NCT NCT07218913
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07218913 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1 Trial of Pedmark in Men Receiving Cisplatin for Metastatic Germ Cell Tumor
Lead sponsor
City of Hope Medical Center
Phase
Phase 1
Overall status
Recruiting
Start date
February 19, 2026
Completion date
January 22, 2031
Enrollment
44 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

hearing loss, metastatic malignant germ cell tumor, metastatic malignant nongerminomatous germ cell tumor, metastatic malignant testicular non-seminomatous germ cell tumor, metastatic testicular seminoma, stage ii testicular cancer ajcc v8, stage iii testicular cancer ajcc v8